LifeVantage (NASDAQ:LFVN) Coverage Initiated by Analysts at Lake Street Capital

Lake Street Capital began coverage on shares of LifeVantage (NASDAQ:LFVN) in a research report report published on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $26.00 price target on the stock.

LifeVantage Stock Performance

LifeVantage stock traded down $0.29 during midday trading on Thursday, reaching $17.44. The company’s stock had a trading volume of 15,388 shares, compared to its average volume of 64,605. LifeVantage has a fifty-two week low of $5.22 and a fifty-two week high of $18.41. The firm has a market capitalization of $218.44 million, a PE ratio of 54.50 and a beta of 0.87. The stock’s 50 day simple moving average is $13.88 and its 200 day simple moving average is $10.24.

LifeVantage (NASDAQ:LFVN) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.15. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%. The business had revenue of $47.21 million during the quarter.

LifeVantage Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were given a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date was Monday, December 2nd. LifeVantage’s dividend payout ratio is presently 50.00%.

Institutional Trading of LifeVantage

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ritholtz Wealth Management increased its position in LifeVantage by 62.0% during the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock worth $346,000 after purchasing an additional 10,974 shares in the last quarter. Barclays PLC increased its position in LifeVantage by 38.2% during the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after purchasing an additional 11,608 shares in the last quarter. Hantz Financial Services Inc. purchased a new stake in LifeVantage in the 2nd quarter valued at about $91,000. Renaissance Technologies LLC grew its holdings in LifeVantage by 2.1% in the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after buying an additional 17,300 shares during the period. Finally, HighTower Advisors LLC purchased a new stake in LifeVantage in the 3rd quarter valued at about $638,000. Hedge funds and other institutional investors own 35.32% of the company’s stock.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.